11 completed, 9 active not recruiting, 4 terminated, 2 unknown. 11 Phase 2, 8 Phase 3, 5 Phase 1, 2 Early Phase 1, 2 Not applicable.
Follow Ovarian Seromucinous Carcinoma: new trials by email Literature Review of Ovarian Seromucinous Carcinoma trials Research Report on Ovarian Seromucinous Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Everolimus, Laboratory Biomarker Analysis, Letrozole - Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Completed | Mayo Clinic | 20 | 2014-11-14 | 2020-10-23 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-09-10 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 16 | 2012-07-09 | 2019-03-12 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2011-10-11 | 2019-07-22 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
Showing 20 of 26. Sign in to see all of them.
Fallopian Tube Neoplasms (23) · Ovarian Neoplasms (20) · Brenner Tumor (14) · Neoplasms (2) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Dysgerminoma (1) · Nausea (1) · Somatostatinoma (1) · Teratoma, Ovarian (1) · Vomiting (1)
Adnexal Diseases (25) · Female Urogenital Diseases (25) · Female Urogenital Diseases and Pregnancy Complications (25) · Genital Diseases (25) · Genital Diseases, Female (25) · Genital Neoplasms, Female (25) · Urogenital Diseases (25) · Urogenital Neoplasms (25) · Endocrine System Diseases (24) · Gonadal Disorders (24) · Neoplasms by Site (24) · Ovarian Diseases (24) · Fallopian Tube Diseases (23) · Neoplasms (23) · Endocrine Gland Neoplasms (20)
Paclitaxel (11) · Taxes (11) · Disulfides (10) · Immunoglobulin G (10) · Bevacizumab (9) · Carboplatin (8) · Doxorubicin (8) · liposomal doxorubicin (8) · Magnetic Resonance Spectroscopy (5) · Gemcitabine (4) · Specimen Handling (4) · Topotecan (3) · cediranib (3) · olaparib (3) · 1,2-diaminocyclohexaneplatinum II citrate (2)
National Cancer Institute (NCI) (12) · Gynecologic Oncology Group (4) · Mayo Clinic (4) · M.D. Anderson Cancer Center (3) · GOG Foundation (2) · University of Washington (1)
United States (26) · Canada (5) · South Korea (4) · Japan (3) · Puerto Rico (3) · Singapore (1)
Jung-min Lee (2) · Amit M Oza (1) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · David Alberts (1) · Don Dizon (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Gerardo Colon-Otero (1) · Henry Pitot (1) · Joan L Walker (1) · John K Chan (1) · Joyce F Liu (1) · Kathryn Pennington (1)
PMID 37185961, PMID 25318437, PMID 25488966, PMID 26933849, PMID 27394382, PMID 28341300, PMID 28438473, PMID 30309721, PMID 31002578, PMID 31722153, PMID 33485453, PMID 35170751, PMID 35290101, PMID 35759733, PMID 36608382, PMID 37702588, PMID 39361946
U10CA180868 (12), U10CA027469 (8), U10CA101165 (3), N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), P30CA015083 (2), P50CA136393 (2), N01CM00039 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1)